89bio, Inc.
89bio, Inc. (ETNB): 2 pipeline candidates · ~17 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.5 months
D/E 0.16 · 6% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for 89bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$129.1M
Quarterly Burn
$100.4M
Runway
16.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| BIO89-100 | Phase 2 |
| Pegozafermin | Phase 3 |
Frequently asked questions
How many drug candidates are in 89bio, Inc.'s pipeline?
89bio, Inc. (ETNB) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is 89bio, Inc.'s lead drug candidate?
89bio, Inc.'s most advanced tracked candidate is BIO89-100 (Phase 2) for NASH - Nonalcoholic Steatohepatitis.
What is 89bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, 89bio, Inc. has approximately 16.5 months of cash runway.
Who is the CEO of 89bio, Inc.?
Chief Executive Officer is the chief executive officer of 89bio, Inc. (ETNB).
Get the full picture on 89bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.